Novo Nordisk A/S (NVO)

Novo Nordisk A/S is a Danish pharmaceutical group whose common stock is represented in the U.S. by an American depositary receipt listed on the NYSE under the symbol NVO. Through its subsidiaries, the company researches, develops, manufactures, and distributes pharmaceutical products. Its operations are organized into two segments: Obesity and Diabetes Care, and Rare Disease. The obesity and diabetes business includes products used in diabetes, obesity, cardiovascular, and other emerging therapy areas, while the rare disease segment covers rare blood disorders, rare endocrine disorders, and hormone replacement therapy. Novo Nordisk also supplies NovoPen 6 and NovoPen Echo Plus smart insulin pens, the Dose Check insulin dose guidance application, as well as growth hormone pens and injection needles. The company serves markets across Europe, North America, Asia, Latin America, the Middle East, and Africa. Founded in 1923 and headquartered in Bagsvaerd, Denmark, Novo Nordisk operates as a global healthcare issuer with a listed depositary receipt in the United States.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.